Therapeutic Efficacy of Bevacizumab for Age-Related Macular Degeneration
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic Efficacy of Bevacizumab for Age-Related Macular Degeneration
Authors
Keywords
-
Journal
DRUGS & AGING
Volume 28, Issue 11, Pages 853-865
Publisher
Springer Nature
Online
2011-10-05
DOI
10.2165/11594720-000000000-00000
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Addressing Missing Data in Clinical Trials
- (2013) Thomas R. Fleming ANNALS OF INTERNAL MEDICINE
- Pharmacotherapy for Neovascular Age-Related Macular Degeneration: An Analysis of the 100% 2008 Medicare Fee-For-Service Part B Claims File
- (2011) Ross J. Brechner et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Comparing protein VEGF inhibitors: In vitro biological studies
- (2011) Lanlan Yu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Inhibition of vascular endothelial growth factor (VEGF) is sufficient to completely restore barrier malfunction induced by growth factors in microvascular retinal endothelial cells
- (2011) H. L. Deissler et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab
- (2011) Paul Mitchell CURRENT MEDICAL RESEARCH AND OPINION
- A review of safety incidents in England and Wales for vascular endothelial growth factor inhibitor medications
- (2011) S P Kelly et al. EYE
- One-year outcome after intravitreal ranibizumab for large, serous pigment epithelial detachment secondary to age-related macular degeneration
- (2011) S Arora et al. EYE
- Retreatment criteria in anti-VEGF therapy of exudative AMD: critical analysis of present regimes and new morphological definition of “lesion activity”
- (2011) Daniel Pauleikhoff et al. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Spectral-Domain versus Time Domain Optical Coherence Tomography before and after Ranibizumab for Age-Related Macular Degeneration
- (2011) Giuseppe Querques et al. OPHTHALMIC RESEARCH
- Cost Effectiveness of Treatments for Wet Age-Related Macular Degeneration
- (2011) Paul Mitchell et al. PHARMACOECONOMICS
- Systemic and Ocular Safety of Intravitreal Anti-VEGF Therapies for Ocular Neovascular Disease
- (2011) Michael Tolentino SURVEY OF OPHTHALMOLOGY
- Polypoidal Choroidal Vasculopathy Masquerading as Neovascular Age-Related Macular Degeneration Refractory to Ranibizumab
- (2010) Alexandros N. Stangos et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Beneficent Persuasion: Techniques and Ethical Guidelines to Improve Patients' Decisions
- (2010) J. S. Swindell et al. ANNALS OF FAMILY MEDICINE
- Risks of Mortality, Myocardial Infarction, Bleeding, and Stroke Associated With Therapies for Age-Related Macular Degeneration
- (2010) Lesley H. Curtis ARCHIVES OF OPHTHALMOLOGY
- Rapid Expansion of Intravitreal Drug Injection Procedures, 2000 to 2008
- (2010) Robert J. Campbell ARCHIVES OF OPHTHALMOLOGY
- Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review
- (2010) C. Schmucker et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Pharmacologic management of neovascular age-related macular degeneration: systematic review of economic evidence and primary economic evaluation
- (2010) William Hodge et al. CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
- Cost-effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration in germany: Model analysis from the perspective of germany's statutory health insurance system
- (2010) Aljoscha S. Neubauer et al. CLINICAL THERAPEUTICS
- The blind leading the blind: Use and misuse of blinding in randomized controlled trials
- (2010) Larry E. Miller et al. Contemporary Clinical Trials
- Intracellular bevacizumab reduces phagocytotic uptake in RPE cells
- (2010) Alexa Klettner et al. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
- Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity
- (2010) Philipp Sebastian Muether et al. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
- Identifying and Eliminating the Roadblocks to Comparative-Effectiveness Research
- (2010) Daniel F. Martin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vision-Related Function after Ranibizumab Treatment by Better- or Worse-Seeing Eye
- (2010) Neil M. Bressler et al. OPHTHALMOLOGY
- Agreement of Time-Domain and Spectral-Domain Optical Coherence Tomography with Fluorescein Leakage from Choroidal Neovascularization
- (2010) Rahul N. Khurana et al. OPHTHALMOLOGY
- Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study
- (2010) Ursula Schmidt-Erfurth et al. OPHTHALMOLOGY
- A COST-EFFECTIVENESS ANALYSIS OF THREE TREATMENTS FOR AGE-RELATED MACULAR DEGENERATION
- (2010) EMILY W. GOWER et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study
- (2009) Geeta A. Lalwani et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Safety Implications of Vascular Endothelial Growth Factor Blockade for Subjects Receiving Intravitreal Anti–Vascular Endothelial Growth Factor Therapies
- (2009) Karl Csaky et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- A Perspective on Commercial Relationships Between Ophthalmology and Industry
- (2009) Lee M. Jampol ARCHIVES OF OPHTHALMOLOGY
- Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials
- (2009) P Mitchell et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Off-Label Use of Bevacizumab for the Treatment of Age-Related Macular Degeneration
- (2009) Focke Ziemssen et al. DRUGS & AGING
- Different properties of VEGF-antagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells
- (2009) Alexa Karina Klettner et al. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
- Pharmaceutical company–sponsored drug trials: what are we to believe?
- (2009) Paul Shekelle JOURNAL OF CLINICAL EPIDEMIOLOGY
- Which Providers Should Communicate Which Critical Information About a New Medication? Patient, Pharmacist, and Physician Perspectives
- (2009) Derjung M. Tarn et al. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
- Continuing Medical Education, Physicians, and Pavlov
- (2008) Paul R. Lichter ARCHIVES OF OPHTHALMOLOGY
- Predicted biological activity of intravitreal VEGF Trap
- (2008) M W Stewart et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Patients’ Beliefs and Preferences Regarding Doctors’ Medication Recommendations
- (2008) Sarah L. Goff et al. JOURNAL OF GENERAL INTERNAL MEDICINE
- Vitreous Levels of Bevacizumab and Vascular Endothelial Growth Factor-A in Patients with Choroidal Neovascularization
- (2008) Qi Zhu et al. OPHTHALMOLOGY
- What are the external influences on information exchange and shared decision-making in healthcare consultations: A meta-synthesis of the literature
- (2008) Michelle Edwards et al. PATIENT EDUCATION AND COUNSELING
- The Reversal of Fortunes: Trends in County Mortality and Cross-County Mortality Disparities in the United States
- (2008) Majid Ezzati et al. PLOS MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now